Patient Convenience Study
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1852
- Registration Number
- NCT02597920
- Locations
- 🇧🇪
1160.247.1019 Boehringer Ingelheim Investigational Site, Braine-l'Alleud, Belgium
🇧🇪1160.247.1018 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1160.247.1020 Boehringer Ingelheim Investigational Site, Brussels, Belgium
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: 14C-BI 409306
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT02597998
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7797
- Registration Number
- NCT02596230
- Locations
- 🇬🇷
University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
🇭🇺Dr. Kenessey Albert Kórház-Rendelõintézet, Balassagyarmat, Balassagyarmat, Hungary
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT02596217
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02589626
- Locations
- 🇯🇵
Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama, Japan
🇯🇵Kubota Clinic, Kanagawa, Kawasaki, Japan
🇯🇵Kunisaki Makoto Clinic, Fukuoka, Fukuoka, Japan
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 269
- Registration Number
- NCT02589639
- Locations
- 🇯🇵
Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan
🇯🇵North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan
🇯🇵Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 977
- Registration Number
- NCT02580591
- Locations
- 🇺🇸
International Research Associates, LLC, Hialeah, Florida, United States
🇺🇸University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Sestron Clinical Research, Marietta, Georgia, United States
Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02579603
- Locations
- 🇺🇸
Western CT Medical Group, P.C., Danbury, Connecticut, United States
🇫🇷HOP Avicenne, Bobigny, France
🇫🇷HOP de la Cavale Blanche, Brest, France
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02577315
- Locations
- 🇷🇺
1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02574845
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany